By Isnaini Azizah 
The dispute centers on AMT-130, UniQure’s investigational gene therapy designed to silence the huntingtin gene, the root cause of the devastating and fatal brain disorder. According to the FDA official, who requested anonymity to discuss sensitive internal deliberations, the agency has formally requested that UniQure initiate a randomized, placebo-controlled study—a "gold standard" trial design that would involve a "sham" surgical procedure for the control group. The official was blunt in their assessment, suggesting that the company is attempting to bypass rigorous scientific scrutiny. "UniQure is the latest company to make a failed therapy for Huntington’s patients," the official stated, adding that the company likely understands "at some deep level" that its previous trials did not meet the mark. Instead of pursuing a new trial, the official accused UniQure of "performing a distorted or manipulated comparison in the mind of FDA."
This administrative broadside follows months of growing friction between the biotech firm and the regulatory body. UniQure has consistently argued that a placebo-controlled trial for AMT-130 is ethically untenable and practically unfeasible. The treatment is not a simple pill or injection; it requires a highly invasive neurosurgical procedure to deliver the gene therapy directly into the striatum of the brain. To conduct a true placebo-controlled study, patients in the control arm would have to undergo general anesthesia for several hours and have holes drilled into their skulls (burr holes) without receiving the actual therapeutic agent. UniQure maintains that exposing vulnerable patients to the risks of major brain surgery without any potential for benefit violates fundamental bioethical principles.
However, the FDA official disputed this characterization of the risks, suggesting that the company’s refusal to conduct such a trial is rooted more in the fear of negative results than in ethical concerns. The official’s remarks underscore a broader, more systemic tension within the FDA under the leadership of Commissioner Marty Makary. In a recent interview with CNBC’s Becky Quick, Makary appeared to take a veiled swipe at UniQure, criticizing unnamed rare disease therapies that rely on weak data. While Makary did not mention UniQure by name, his description of a gene therapy for Huntington’s disease that lacked sufficient clinical evidence was unmistakable to industry observers.
The conflict is emblematic of a larger debate regarding the FDA’s use of "external controls" in drug approvals. Because Huntington’s disease is a rare condition with a predictable but slow decline, UniQure attempted to support its application by comparing the progress of patients treated with AMT-130 against a database of untreated patients—a method known as a natural history or external control. This approach is increasingly sought by biotech companies working on rare diseases where recruiting large numbers of patients for traditional trials is difficult. UniQure has alleged that the FDA previously signaled receptivity to this data, only to reverse its stance late in the process.
The FDA official vehemently denied any such "about-face." The agency, according to the official, "never agreed to accept this distorted comparison" and noted that the FDA "never makes such assurances" before reviewing the full data set. The official emphasized that the agency’s stance has always been to wait and see if the data is robust enough to overcome the inherent biases of external controls. The official’s assertion that UniQure is "manipulating" the comparison suggests that the agency found significant flaws in how the company matched its treated patients with the historical database, potentially leading to an overestimation of the drug’s benefits.
UniQure responded to these accusations with a forceful statement of its own, defending the integrity of its research and calling the anonymous leaks from the FDA "highly irregular" and "unprecedented." The company expressed confidence in the strength of the data submitted and argued that the anonymous comments did not reflect a "fair and faithful reading" of the official documents exchanged between the two parties. "The recent statements made by anonymous FDA sources to the press… are incomplete or entirely incorrect," the company stated, highlighting the damage such public comments can do to the regulatory process and investor confidence.
The backdrop to this spat is a period of perceived instability within the FDA. Recent months have seen the agency come under fire for a string of drug application rejections, leading some "FDA watchers" to warn of internal chaos and shifting goalposts that could delay life-saving treatments. Critics of the agency argue that a lack of clear, consistent guidance is stifling innovation, particularly in the high-stakes field of gene therapy. Conversely, proponents of the FDA’s current rigor argue that the agency must remain a bulwark against "regulatory capture" and ensure that companies do not use the emotional weight of rare diseases to push through ineffective or unsafe products.
Huntington’s disease remains one of the most challenging targets in modern medicine. It is a progressive, inherited condition that causes the breakdown of nerve cells in the brain, leading to a loss of motor control, cognitive decline, and psychiatric symptoms. Most patients die within 15 to 20 years of the onset of symptoms. The field has been littered with high-profile failures; in recent years, pharmaceutical giants like Roche and Wave Life Sciences have seen their Huntington’s programs stumble in clinical trials. This history of failure likely contributes to the FDA’s skepticism toward UniQure’s data, as the agency is wary of granting approval to a treatment that may only offer a marginal or illusory benefit.
AMT-130 works by using a viral vector to deliver a microRNA (miRNA) that targets and degrades the huntingtin messenger RNA. By reducing the production of the toxic huntingtin protein, the therapy aims to slow or stop the progression of the disease. Early data from UniQure’s small-scale trials suggested some stabilization in biomarkers and functional measures, which the company used to bolster its case for an accelerated approval pathway. However, the FDA’s demand for a placebo-controlled trial suggests that these early signals were not nearly enough to convince regulators of the drug’s clinical meaningfulness.
The financial fallout for UniQure has been significant, though volatile. On the day of the FDA official’s comments, the company’s stock actually rose 18%, a move some analysts attributed to "short squeezing" or a belief among some investors that the public nature of the fight might force a political resolution or a compromise. Nevertheless, the broader picture is bleak for shareholders; the stock has plummeted 56% this year as of Thursday’s close, reflecting the immense uncertainty surrounding its lead program. For a mid-sized biotech company like UniQure, the cost of a new, multi-year, placebo-controlled brain surgery trial could be prohibitive, potentially forcing the company to seek a larger partner or significantly scale back its operations.
The situation also raises questions about the future of gene therapy for neurological disorders. If the FDA remains firm in its requirement for sham surgeries in control groups, it could set a high bar that discourages investment in surgical gene deliveries. Patient advocacy groups are also watching the situation closely. Many Huntington’s families, who face a 100% fatal prognosis, have expressed a willingness to accept higher levels of uncertainty and risk in exchange for access to potentially disease-modifying therapies. The clash between these desperate patient needs and the FDA’s mandate for "substantial evidence" of efficacy remains the central tension of modern drug regulation.
As the "messy public spat" continues, the industry is left wondering whether this is an isolated incident involving one company’s data or a sign of a more aggressive, skeptical FDA under the current administration. For now, UniQure remains at a standstill with the agency, and the thousands of patients suffering from Huntington’s disease are left waiting for clarity on whether a treatment that once seemed promising will ever reach the market. The FDA official’s parting shot—that UniQure should "do the right thing and run the correct clinical study"—suggests that unless the company yields to the agency’s demands, the path forward for AMT-130 may be permanently blocked.